Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations

Table 2 Process for listing high-cost medicines in Australia, England, and South Korea

Process for listing high-cost medicines	Australia	England	South Korea
Responsible parties in each step for listing of high-cost medicines
Submit the application	Sponsor* company submits a dossier after medicine is rejected by PBS	All novel cancer medicines submitted by sponsor	Application and related dossier submitted by sponsor company
Review the evidence	LSDP expert panel	NICE appraisal committee	HIRA—BCA committee and EE sub-Committee
Appraise the evidence	Chief Medical Officer (LSDP)	NICE advisory committee	PBC
Time for appraisal	2–6 weeks	90 days	120 days
Price Negotiations	MoH and Sponsor	NHS and Sponsor	NHIS and Sponsor
Final decision	MoH	NICE	MOHW
Re-evaluation	MoH every 2 years	NICE every 2 years	MOHW every 2 years

BCA Benefit Criteria Advisory, EE economic evaluation, HIRA Health Insurance Review and Assessment Service, LSDP Life Saving Drug Program, MoH Ministry of Health, MOHW Ministry of Health and Family Welfare, NICE National Institute for Health and Care Excellence, NHIS National Health Insurance Service, PBC Pharmaceutical Benefits Committee
*Sponsor: a pharmaceutical manufacturer or any company that nominates a medicine for listing

ISSN: 2052-3211